CXCR7 GPCR insurmountable antagonist
target engagement in rodent, 61% F in dog
from 300k HTS vs. β-arrestin recruitment, opt.
J. Med. Chem., Dec. 14, 2020
Idorsia Pharma (Actelion), Allschwil, CH
Idorsia/Actelion CXCR7 GPCR insurmountable antagonist